Stabilized compositions comprising cannabidiol
View Patent ↗Compositions and methods of use of treatment of one or more of ovarian cancer, endometrial cancer, head and neck cancer, noncancerous gynecological disorders, and estrogen sensitive cancers, the composition comprising an effective amount of a cannabinoid and a flavonoid wherein the method comprises administering to a patient in need thereof an effective amount of the composition and optionally administering the composition concomitantly with a chemotherapeutic agent.
1. A composition for treatment of noncancerous gynecological disorders or gynecological cancers comprising cannabidiol (CBD) from an isolate or extract at between 50% and 99.9% by weight of the composition and a flavonoid at between 0.1% and 50% by weight of the composition, said flavonoid selected from the group consisting of: myricetin, chrysin, taxifolin, galangin, luteolin, 3-hydroxyflavone, and combinations thereof.
2. The composition of claim 1 wherein the cannabidiol is provided from a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), a CBD isolate, cannabidiolic acid (CBDA), and combinations thereof.
3. The composition of claim 1 wherein the cannabidiol is provided from a BSHE or FSHE and comprises (i) from 50% to 99.9% by weight of CBD and (ii) at least one other cannabinoid selected from Δ-9-tetrahydrocannabinol (Δ9-THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ8-THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.
4. The composition of claim 3 wherein at least a portion of the CBD is synthetic.
5. The composition of claim 1 wherein the flavonoid has a concentration of at least 50 μM.
6. The composition of claim 1 wherein the composition is substantially free of tocopherol.
7. The composition of claim 1 which is suitable for administration orally, rectally, via an oral mucosa, via a vaginal mucosa, via a nasal mucosa, dermally, subcutaneously, or intravenously.
8. The composition of claim 1 wherein the ratio of the cannabidiol to the flavonoid is 5 μg/mL: 1 μM to 5 μg/mL:200 μM and all ratios in between.
9. The composition of claim 1 wherein the composition comprises a carrier; and the composition has a pH of between 3.5 to 6.
10. A method of treatment of a gynecological disease or disorder comprising administering to a patient in need thereof an effective amount of a composition comprising cannabidiol (CBD) at between 50% and 99.9% by weight of the composition and a flavonoid at between 0.1% and 50% by weight of the composition, the flavonoid selected from the group consisting of: myricetin, chrysin, taxifolin, galangin, luteolin, 3-hydroxyflavone, and combinations thereof.